eli-002
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 4, 2021 (NCT04853017)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 1
- Genes, ras · Phase 1/Phase 2
- Neoplasm, Residual · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- ras GTPase-Activating Proteins · Phase 1/Phase 2
- ras Proteins · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05726864 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2023 | Elicio Therapeutics |
| NCT04853017 | Phase 1 | Oct 4, 2021 | Elicio Therapeutics |
| NCT07083479 | N/A | — | Elicio Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elicio Therapeutics | For profit | 3 | 3 | 3 | 2021 |
1 organizations
Page 1 / 1